Can Cost Cuts And 2030 Targets Really Save Pfizer Stock?
The company now leads with a cost-savings total and a growth rate that does not begin until the…
Can Eli Lilly Stock Keep Surging As Drug Prices Fall?
The past year’s gain was bought with volume and access, and management has already said net price goes…
Eli Lilly Found a New Gear. You Paid For It.
Beyond strong drugs, the stock’s ascent was powered by its notable profitability. You watched Eli Lilly (LLY) climb…
Pfizer Stock Is A Race Between New Drugs And Old Patents
The medicines Pfizer has launched and acquired are arriving at close to the scale of the revenue its…
Why Isn’t Eli Lilly Stock Trading At The Top Of Its Peer Group?
The market seems to have its pharma giants ranked in a peculiar order, leaving one of the group’s…
Johnson & Johnson Is Becoming A Narrower Company Than You Bought
Management’s plain health care label has slipped out of the lead, and the business now on a separation…
64 Years Old With $1.1 Million in a Traditional IRA. Here’s Where I’m Allocating Capital
Quick Read KO and ABBV anchor the portfolio at 25% each, rated Very Safe with payout ratios under…
Everyone Is Watching Eli Lilly Stock’s New Drugs. Here Is the Metric That Vanished
Management once made manufacturing its top priority; now that the topic has gone quiet, it reveals just how…
The Catch Hiding In Eli Lilly Stock’s Growth Story
Eli Lilly’s obesity drug franchise is a juggernaut, but a surprisingly large share of its success relies on…
ABBV Buys Rights to Bretisilocin, a Novel Psychedelic for Depression
AbbVie ABBV has announced a deal with private neuroscience biotech, Gilgamesh Pharmaceuticals, to acquire the latter’s lead pipeline…